



SAFETY DATA SHEET

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

Product:	AIR-SHIELD™ LM (ALL SEASON)	Part Number: 6516-0000
Manufacturer:	W. R. MEADOWS OF CANADA	Address: 70 Hannant Court Milton, Ontario Canada L9T 5C1
Telephone:	(905) 878-4122	In case of emergency, dial (800) 424-9300 (CHEMTREC)
Revision Date:	4/20/2020	
Product Use:	Air/Vapor Liquid Moisture Barrier	

SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS	HAZARD STATEMENTS
	WARNING!
Health	1 Flammable liquid and vapor.
Flammability	2 Causes skin, eye, respiratory irritation.
Reactivity	0 Suspected of causing genetic defects.
Personal Protection	Causes damage to liver, kidneys, lungs, and blood. Harmful if inhaled. May be fatal if ingested and enters airway.
	PRECAUTIONARY STATEMENTS
	Use only in well-ventilated areas.
	Avoid breathing vapors and direct contact.
	Store in well-ventilated location.
	Wear appropriate personal protective equipment.
	Keep away from ignition sources.
	Control vapors in confined spaces utilizing mechanical ventilation.



SECTION 3: HAZARDS COMPONENTS

<u>Chemical Name:</u>	<u>CAS Number</u>	<u>% by Weight</u>	<u>SARA 313</u>	<u>Vapor Pressure (mm Hg@20°C)</u>	<u>LEL (@25°C)</u>
1. Xylene	1330-20-7	1-5	Yes	6.6	1.1
2. Light Aromatic Naphtha	64742-95-6	20-25	No	<10 @ 25°C	0.9
3. Petroleum Asphalt	8052-42-4	30-35	No	N/A	N/A
4. Petroleum Oil	64742-52-5	5-10	No	N/A	N/A
5. 1,2,4-Trimethylbenzene	95-63-6	5-10	Yes	N/A	0.9

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313." *N/A: Not Applicable*

SECTION 4: EMERGENCY AND FIRST AID PROCEDURES

EYE CONTACT: Move victim from exposure source and into fresh air. Flush eyes with water for Fifteen (15) minutes. If symptoms persist, seek medical attention.

SKIN CONTACT: Wash affected areas with mild soap and water. Product may be difficult to remove. Do not use petroleum solvents.

INHALATION: If respiratory symptoms develop, move victim from exposure source and into fresh air. If symptoms persist, seek medical attention.

INGESTION: Not anticipated to be an exposure route. If ingested, do not induce vomiting. Dilute by giving victim water or milk. Seek immediate medical attention.

MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC: See Section Eleven for Symptoms/Effects.

SECTION 5: FIRE AND EXPLOSIVES HAZARDS

FLASHPOINT: 52 °C (Method 1010 A)

EXTINGUISHING MEDIA: Water fog, foam, dry chemical, or carbon dioxide.

CHEMICAL/COMBUSTION HAZARDS: Oxides/compounds of nitrogen/sulfur, carbon dioxide, carbon monoxide, and incomplete combustion products.

PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT: Avoid direct contact. Use of eye protection and chemical-resistant gloves is recommended. Respiratory protection may be required if excessive vapor concentrations are present.

SAFETY DATA SHEET

Date of Preparation: **4/20/20** Page 2 of 3 6516-000

SECTION 6: ACCIDENTAL RELEASE MEASURES

SPILL OR LEAK PROCEDURES: Evacuate the hazard area of unprotected personnel. Remove/extinguish ignition sources. Dike and contain. Wear appropriate personal protective equipment. Place spilled material in sealed/marked containers for disposal.

SECTION 7: HANDLING AND STORAGE

SAFE HANDLING PROCEDURES: Avoid direct contact. For exterior use only. Avoid ignition sources.
SAFE STORAGE: Keep containers closed when not in use. Store away from ignition sources.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Chemical Name:	OSHA					ACGIH			
	PEL	PEL/CEILING	PEL/STEL	SKIN	TWA	TLV/CEILING	TLV/STEL	SKIN	
1. Xylene	100 ppm	N/E	N/E	N/E	100 ppm	N/E	150 ppm	N/E	
2. Light Aromatic Naphtha	N/E	N/E	N/E	N/E	N/E	N/E	N/E	N/E	
3. Petroleum Asphalt	5 mg/m ^{3*}	N/E	N/E	N/E	5 mg/m ^{3*}	N/E	N/E	N/E	
4. Petroleum Oil	5 mg/m ³⁺	N/E	N/E	N/E	5 mg/m ³⁺	N/E	10 mg/m ³⁺	N/E	
5. 1,2,4-Trimethylbenzene	25 ppm	N/E	N/E	No	25 ppm	N/E	N/E	No	

* : Asphalt Fumes + : Petroleum Oil mist in air N/E: Not Established

ENGINEERING CONTROLS: Use with adequate ventilation. Use explosion-proof equipment.

PERSONAL PROTECTIVE EQUIPMENT: Safety glasses, chemical-resistant gloves.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

BOILING POINT: 134 °C for Xylene	VAPOR DENSITY: >1 (air=1)	% VOLATILE BY VOLUME: N/E
EVAPORATION RATE: <1 (ether=1)	pH LEVEL: N/A	% VOLATILE BY WEIGHT: 36 (approximate)
WEIGHT PER GALLON: 8.62	PRODUCT APPEARANCE: Black, Heavy Paste	VOC CONTENT: 371 g/L
ODOR: Mild Solvent	ODOR THRESHOLD: N/D	MELTING/FREEZING POINT: N/D
FLASH POINT: See Section 5	FLAMMABILITY: N/D	UEL/LEL: N/D
VAPOR PRESSURE: N/D	RELATIVE DENSITY: N/D	SOLUBILITY: N/D
PARTITION COEFFICIENT: N/D	AUTOIGNITION TEMPERATURE: N/D	DECOMPOSITION TEMPERATURE: N/D
VISCOSITY: N/D		N/D: Not Determined

SECTION 10: STABILITY/REACTIVITY

STABILITY: Stable.

HAZARDOUS POLYMERIZATION: Will not occur.

CONDITIONS AND MATERIALS TO AVOID: Oxidizing agents, strong acids, strong alkalis.

HAZARDOUS DECOMPOSITION PRODUCTS: Carbon dioxide, carbon monoxide, oxides/compounds of nitrogen/sulfur, and incomplete combustion products.

SECTION 11: TOXICOLOGICAL INFORMATION

EYE CONTACT: Direct contact may result in moderate irritation. Product vapors/mists may also cause irritation.

SKIN CONTACT: Direct contact may cause mild skin irritation. Prolonged/repeated contact may result in skin irritation/dermatitis.

INHALATION: Exposure to excessive vapor concentrations may result in transient central nervous system depression (headache, fatigue, drowsiness, loss of coordination). Intentional misuse by deliberately concentrating/inhaling vapors may be harmful or fatal. Repeated/prolonged occupational exposures to solvents may cause permanent brain and nervous system damage.

INGESTION: Not anticipated to be an exposure route. Ingestion will cause irritation of the digestive tract.

SIGNS AND SYMPTOMS: Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include redness and swelling. Gastrointestinal irritation symptoms include nausea, vomiting, and abdominal discomfort. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function. Symptoms of transient central nervous system depression include: headache, fatigue, drowsiness, dizziness, and loss of coordination.

AGGRAVATED MEDICAL CONDITIONS: Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product.

OTHER HEALTH EFFECTS: Xylene can cause damage to the following organs: blood, kidneys, lungs, liver, mucous membranes, heart, upper respiratory tract, skin, auditory system, central nervous system and eyes. Some asphalts may possess weak carcinogenic activity. Repeated direct skin contact should be avoided. Occasional contact with asphalt is not expected to have serious health effects as long as good personal hygiene measures are followed.

SAFETY DATA SHEET

Date of Preparation: 4/20/20	Page 3 of 3	6516-000
SECTION 12: ECOLOGICAL INFORMATION		
ECOTOXICITY: N/E	DEGRADABILITY: N/E	BIOACCUMULATIVE POTENTIAL: N/E
SOIL MOBILITY: N/E	OTHER ADVERSE EFFECTS: N/E	
SECTION 13: WASTE DISPOSAL INFORMATION		
WASTE DISPOSAL INFORMATION: Product will be classified as a hazardous waste (D001). Suitable for fuel blending.		
SECTION 14: TRANSPORTATION INFORMATION		
HAZARDOUS/NON-HAZARDOUS MATERIAL: Not regulated by domestic ground shipment.		
UN NUMBER: None	HAZARD CLASS: None	PACKING GROUP: None
UN PROPER SHIPPING NAME: None.		
ENVIRONMENTAL HAZARDS: None recognized.		
BULK TRANSPORTATION INFORMATION: Not applicable. Product not supplied in bulk configuration.		
SPECIAL PRECAUTIONS: None.		
SECTION 15: REGULATORY INFORMATION		
OTHER REGULATORY CONSIDERATIONS: None recognized.		
SECTION 16: OTHER INFORMATION		
PREPARATION DATE:	4/20/2020	
PREPARED BY:	Dave Carey	

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.
